Concordare Trials Secures Funding Round to Accelerate Digitization of Clinical Trial Protocols

AI-powered platform converts PDF protocols into structured digital format, accelerating site activation by 6-8 weeks

Concordare Trials closed a funding round led by Surface Ventures with participation from Techstars, Innovation Works, Gaingels, and individual investors. The company converts static clinical trial protocol PDFs into a structured, interoperable digital format every downstream system can use.

“Every day a trial runs late, a patient is waiting,” said Zach Sawaged, CEO and founder of Concordare Trials. “We built software that addresses the source of clinical trial inefficiencies in a way that works for sites across every sponsor, every study, every time. This funding accelerates that work.”

After a decade working across clinical research sites, sponsors, and technology vendors, Sawaged saw firsthand how much cost and delay stem from recreating protocol information in different systems, so he developed a solution himself. Drawing from experience at NYU Langone, Amgen, Johnson & Johnson, Takeda, and Veeva, he founded Concordare.

Despite years of investment in software systems for clinical operations, the clinical research industry never addressed the structural gap at the center of every study: the protocol itself. Manual configuration against lengthy, non-standardized protocols costs an estimated $25 million per study.

The Concordare Suite™ ingests any protocol PDF and converts it into the company’s proprietary CTPM (Clinical Trial Protocol Model), a digital, system-agnostic source of truth for a trial. AI is used exclusively for protocol extraction. The CTPM is human-reviewed before generating system configurations and study documents, maintaining protocol fidelity and study integrity.

Sites apply this workflow once across studies, and end users can build downstream outputs in seconds, accelerating study activation by 6-8 weeks.

“By digitizing clinical trial protocols at an early point in the process, Concordare has the opportunity to further digitize the entire clinical trial value chain and create value for both sponsors and sites,” said Gyan Kapur, Co-Managing Partner at Surface Ventures. “This enables trials to run faster with fewer errors, ultimately helping get life-saving treatments to patients sooner.”

Concordare's partner network includes leading academic medical centers with longtime partner Rutgers University leveraging the platform across multiple teams. The company is currently contracting with additional institutions nationwide.

The funding round supports product development, team expansion, and the growth of Concordare’s site partnership network. Learn more at https://concordare.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825901105/en/

“This enables trials to run faster with fewer errors, ultimately helping get life-saving treatments to patients sooner.”